Novel Chronic Mouse Model of Cerebral Cavernous Malformations

Area of Science:

• Neuroscience
• Genetics
• Pharmacology

Background:

• Cerebral cavernous malformations (CCMs) are brain vascular defects causing hemorrhages.
• Existing acute mouse models have short lifespans, limiting evaluation of curative drug effects.
• A need exists for chronic models to test treatments for pre-existing CCM lesions.

Purpose of the Study:

• To develop and characterize a novel chronic mouse model for CCMs.
• To evaluate the curative potential of indirubin-3'-monoxime in this chronic model.

Main Methods:

• A chronic CCM mouse model was created using postnatal, brain-endothelial-cell-specific ablation of the Ccm2 gene.
• The model utilized the inducible Slco1c1-CreER(T2) mouse line for controlled gene deletion.
• Lesion burden and hemorrhages were quantified over time; indirubin-3'-monoxime was administered to 3-month-old mice.

Main Results:

• A fully penetrant chronic CCM mouse model with long-term survival and no off-target effects was established.
• CCM lesions and intracerebral hemorrhages developed by 3 months of age.
• Indirubin-3'-monoxime treatment (20 mg/kg for 3 weeks) showed no beneficial effect on lesion burden or hemorrhages.

Conclusions:

• The developed chronic CCM mouse model is a valuable tool for studying CCM pathogenesis and testing curative therapies.
• Indirubin-3'-monoxime lacks curative effects on established CCM lesions and associated hemorrhages in this model.
• Further research is needed to identify drugs with curative potential for pre-existing CCM lesions.